16175-04-5

Basic information

• Product Name: 2-(4-methoxy-phenylsulfanyl)-phenyl acetic acid
• Synonyms: 2-(4-methoxy-phenylsulfanyl)-phenyl acetic acid
• CAS NO: 16175-04-5
• Molecular Weight: 274.34
• Mol File: 16175-04-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-(4-methoxy-phenylsulfanyl)-phenyl acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-methoxy-phenylsulfanyl)-phenyl acetic acid(16175-04-5)
• EPA Substance Registry System: 2-(4-methoxy-phenylsulfanyl)-phenyl acetic acid(16175-04-5)

Safety Data

• Hazardous Substances Data: 16175-04-5(Hazardous Substances Data)

Upstream product

• 16175-01-2 2-(4-methoxyphenyl)sulfanylbenzylalcohol 
• 19862-91-0 2-<(4-methoxyphenyl)thio>benzoic acid 
• 16175-02-3 C₁₄H₁₃ClOS 
• 696-63-9 4-Methoxybenzenethiol 
• 18698-96-9 o-iodophenylacetic acid 

Downstream Products

• 1191112-15-8 benzyl 2-(2-(4-methoxyphenylthio)phenyl)acetate 
• 43183-16-0 [2-(4-hydroxy-phenylsulfanyl)-phenyl]acetic acid 

Relevant articles and documents

DIHYDROBENZO[B][1]BENZOTHIEPIN COMPOUNDS USEFUL IN THERAPY

The present invention relates to the use of a compound of formula (I), to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject.

Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors

Overexpression of macrophage elastase (MMP-12), a member of the matrix metalloproteinases family, can be linked to tissue remodeling and degradation in some inflammatory processes, such as chronic obstructive pulmonary disease (COPD), emphysema, rheumatoi

Derivatives of hydroxyphenylsulfanylbenzoic and hydroxphenylsulfanylarylacetic acids

Processes for the preparation of derivatives of hydroxyphenylsulfanylbenzoic and hydroxyphenylsulfanylarylacetic acids of Formula (I) and pharmaceutical compositions including these compounds are provided: wherein X is H, halogen or NO2group, n is 0 or 1, and m is 2 to 4 if Z is either 4-acetyl-3 -hydroxy-2-propylphenoxy of Formula (II): or a piperazinyl residue, or m is 1 if Z is quinolin-2-yl or 6-chloroquinoli-2-yl.